/Revvity%20Inc_%20logo%20on%20phone%20and%20site%20by-%20T_Schneier%20via%20Shutterstock.jpg)
Valued at a market cap of $11.6 billion, Revvity, Inc. (RVTY) provides health sciences solutions, technologies, and services. The Waltham, Massachusetts-based company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. It is expected to announce its fiscal Q2 earnings for 2025 before the market opens on Monday, Jul. 28.
Ahead of this event, analysts expect this healthcare company to report a profit of $1.14 per share, down 6.6% from $1.22 per share in the year-ago quarter. The company has topped Wall Street’s earnings estimates in each of the last four quarters. In Q1, Revvity’s EPS of $1.01 outpaced the forecasted figure by 5.2%.